This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Lloyd Mitchell Segal net worth and biography

Lloyd Segal Biography and Net Worth

CEO of Repare Therapeutics

Lloyd M. Segal has served as our President and Chief Executive Officer and as a member of our board of directors since our incorporation in September 2016. From February 2010 to January 2016, he was a Managing Partner with Persistence Capital Partners, a Canadian-based healthcare private equity investor. Previously, Mr. Segal was a consultant with McKinsey & Company, and served as chief executive officer of several emerging biotechnology companies including Advanced Bioconcept Inc., Caprion Pharmaceuticals Inc. (now Caprion Biosciences), which he co-founded, and Thallion Pharmaceuticals Inc.

He serves as a member of the board of directors of GBC American Fund, a U.S. growth-focused mutual fund. Mr. Segal also previously served as Chairman of LMC Diabetes & Endocrinology, Canada’s leading national endocrinology practice. From June 2016 to March 2020, Mr. Segal served as Entrepreneur-in-Residence with Versant Ventures. He was honored in 2013 by the Financial Times as Outstanding Director of the Year for public companies and also previously served on the boards of directors of several public and private U.S. and Canadian companies, including Valeant Pharmaceuticals International and its predecessor company, Biovail Corporation.

He holds a B.A. in politics from Brandeis University and an M.B.A. from Harvard Business School. Our board of directors believes that Mr. Segal’s extensive experience in the biotechnology industry in addition to his corporate governance and executive leadership experience qualify him to serve on our board of directors.

What is Lloyd Mitchell Segal's net worth?: The estimated net worth of Lloyd Mitchell Segal is at least $147,354.46 as of April 1st, 2024. Mr. Segal owns 107,558 shares of Repare Therapeutics stock worth more than $147,354 as of December 18th. This net worth evaluation does not reflect any other investments that Mr. Segal may own. Additionally, Mr. Segal receives an annual salary of $932,180.00 as CEO at Repare Therapeutics. Learn More about Lloyd Mitchell Segal's net worth.
How old is Lloyd Mitchell Segal?: Mr. Segal is currently 60 years old. There are 3 older executives and no younger executives at Repare Therapeutics. Learn More on Lloyd Mitchell Segal's age.
What is Lloyd Mitchell Segal's salary?: As the CEO of Repare Therapeutics Inc., Mr. Segal earns $932,180.00 per year. Learn More on Lloyd Mitchell Segal's salary.
How do I contact Lloyd Mitchell Segal?: The corporate mailing address for Mr. Segal and other Repare Therapeutics executives is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. Repare Therapeutics can also be reached via phone at 857-412-7018 and via email at [email protected]. Learn More on Lloyd Mitchell Segal's contact information.
Has Lloyd Mitchell Segal been buying or selling shares of Repare Therapeutics?: Lloyd Mitchell Segal has not been actively trading shares of Repare Therapeutics over the course of the past ninety days. Most recently, Lloyd Mitchell Segal sold 2,491 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $4.63, for a transaction totalling $11,533.33. Following the completion of the sale, the chief executive officer now directly owns 107,558 shares of the company's stock, valued at $497,993.54. Learn More on Lloyd Mitchell Segal's trading history.
Who are Repare Therapeutics' active insiders?: Repare Therapeutics' insider roster includes David Bonita (Director), Thomas Civik (Director), Todd Foley (Director), Ansbert Gadicke (Major Shareholder), Lloyd Segal (CEO), and Michael Zinda (EVP). Learn More on Repare Therapeutics' active insiders.
Are insiders buying or selling shares of Repare Therapeutics?: In the last twelve months, insiders at the sold shares 9 times. They sold a total of 11,540 shares worth more than $54,037.47. The most recent insider tranaction occured on April, 1st when CEO Lloyd Mitchell Segal sold 2,491 shares worth more than $11,533.33. Insiders at Repare Therapeutics own 21.6% of the company. Learn More about insider trades at Repare Therapeutics.
Information on this page was last updated on 4/1/2024.

Lloyd Mitchell Segal Insider Trading History at Repare Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2024	Sell	2,491	$4.63	$11,533.33	107,558
3/27/2024	Sell	2,650	$4.63	$12,269.50	83,866
3/25/2024	Sell	2,650	$4.79	$12,693.50	89,166
6/9/2021	Sell	1,576	$35.00	$55,160.00	5,000
6/4/2021	Sell	5,000	$31.25	$156,250.00	10,000
5/20/2021	Sell	3,770	$35.03	$132,063.10
5/18/2021	Sell	1,800	$35.00	$63,000.00	5,000
4/15/2021	Sell	5,512	$35.01	$192,975.12	5,000

Lloyd Mitchell Segal Buying and Selling Activity at Repare Therapeutics

Repare Therapeutics Company Overview

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Today's Range

Now: $1.37

$1.33

$1.53

50 Day Range

MA: $3.22

$1.46

$3.97

2 Week Range

Now: $1.37

$1.33

$8.49

Volume

351,177 shs

Average Volume

197,891 shs

Market Capitalization

$58.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

Lloyd Segal Biography and Net Worth

What is Lloyd Mitchell Segal's net worth?

How old is Lloyd Mitchell Segal?

What is Lloyd Mitchell Segal's salary?

How do I contact Lloyd Mitchell Segal?

Has Lloyd Mitchell Segal been buying or selling shares of Repare Therapeutics?

Who are Repare Therapeutics' active insiders?

Are insiders buying or selling shares of Repare Therapeutics?